New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
Ineffective painkillers are widely prescribed to patients with inflammatory arthritis in England, research finds

Ineffective painkillers are widely prescribed to patients with inflammatory arthritis in England, research finds

byKeele UniversityAnnual prevalence of all analgesic (A) and opioid strength (B) prescriptions in patients with inflammatory arthritis. AxSpA: axial spondyloarthritis; IA: inflammatory arthritis
Arthritis and Rheumatism February 18,2024
Ineffective painkillers are widely prescribed to patients with inflammatory arthritis in England, research finds

Ineffective painkillers are widely prescribed to patients with inflammatory arthritis in England, research finds

byKeele UniversityAnnual prevalence of all analgesic (A) and opioid strength (B) prescriptions in patients with inflammatory arthritis. AxSpA: axial spondyloarthritis; IA: inflammatory arthritis
Arthritis and Rheumatism February 18,2024
Contraceptive pills can lower the risk of rheumatoid arthritis, study finds

Contraceptive pills can lower the risk of rheumatoid arthritis, study finds

by Gustav Löfgren, Schwedischer Forschungsrat - The Swedish Research CouncilDirected Acyclic Graph (DAG) (12) on the association of exogenous hormones and Rheumatoid Arthritis (RA). For oral contracep
Arthritis and Rheumatism February 18,2024
Contraceptive pills can lower the risk of rheumatoid arthritis, study finds

Contraceptive pills can lower the risk of rheumatoid arthritis, study finds

by Gustav Löfgren, Schwedischer Forschungsrat - The Swedish Research CouncilDirected Acyclic Graph (DAG) (12) on the association of exogenous hormones and Rheumatoid Arthritis (RA). For oral contracep
Arthritis and Rheumatism February 18,2024
CBD as a painkiller: Efficacy not clinically proven

CBD as a painkiller: Efficacy not clinically proven

byMedical University of ViennaCredit: Pixabay/CC0 Public DomainCannabidiol (CBD) is marketed by some suppliers as a painkiller, e.g., for osteoarthritis of the knee. Animal experiments have show
Arthritis and Rheumatism February 18,2024
CBD as a painkiller: Efficacy not clinically proven

CBD as a painkiller: Efficacy not clinically proven

byMedical University of ViennaCredit: Pixabay/CC0 Public DomainCannabidiol (CBD) is marketed by some suppliers as a painkiller, e.g., for osteoarthritis of the knee. Animal experiments have show
Arthritis and Rheumatism February 18,2024
Study finds JAK inhibitors and tocilizumab effective in VEXAS syndrome

Study finds JAK inhibitors and tocilizumab effective in VEXAS syndrome

byAmerican College of RheumatologyCredit: CC0 Public DomainNew research at ACR Convergence 2023, the American College of Rheumatology's (ACR) annual meeting, found that JAK inhibitors (JAKi)
Immunology & Rheumatology February 18,2024
Study finds JAK inhibitors and tocilizumab effective in VEXAS syndrome

Study finds JAK inhibitors and tocilizumab effective in VEXAS syndrome

byAmerican College of RheumatologyCredit: CC0 Public DomainNew research at ACR Convergence 2023, the American College of Rheumatology's (ACR) annual meeting, found that JAK inhibitors (JAKi)
Immunology & Rheumatology February 18,2024
21.2 percent of US adults had diagnosed arthritis from 2019 to 2021

21.2 percent of US adults had diagnosed arthritis from 2019 to 2021

by Elana GotkineAn estimated 21.2 percent of U.S. adults had diagnosed arthritis from 2019 to 2021, with most cases among adults aged 45 years and older, according to research published in the Oct. 13
Immunology & Rheumatology February 18,2024
21.2 percent of US adults had diagnosed arthritis from 2019 to 2021

21.2 percent of US adults had diagnosed arthritis from 2019 to 2021

by Elana GotkineAn estimated 21.2 percent of U.S. adults had diagnosed arthritis from 2019 to 2021, with most cases among adults aged 45 years and older, according to research published in the Oct. 13
Immunology & Rheumatology February 18,2024
Does this cause cancer? How scientists determine whether a chemical is carcinogenic

Does this cause cancer? How scientists determine whether a chemical is carcinogenic

by Brad Reisfeld,The ConversationPeople areexposed to numerous chemicalsthroughout their lifetimes. These chemicals can be from the air, foods, personal care items, household product
Oncology February 18,2024
Does this cause cancer? How scientists determine whether a chemical is carcinogenic

Does this cause cancer? How scientists determine whether a chemical is carcinogenic

by Brad Reisfeld,The ConversationPeople areexposed to numerous chemicalsthroughout their lifetimes. These chemicals can be from the air, foods, personal care items, household product
Oncology February 18,2024
Researchers image live drug response and resistant 'pockets' in pancreatic cancer

Researchers image live drug response and resistant 'pockets' in pancreatic cancer

by Garvan Institute of Medical ResearchSchematic of spatiotemporal AKT activity mapping in several organ systems in vivo.Optical window–mediated intravital assessment of metabolic and malignancy-
Oncology February 18,2024
Researchers image live drug response and resistant 'pockets' in pancreatic cancer

Researchers image live drug response and resistant 'pockets' in pancreatic cancer

by Garvan Institute of Medical ResearchSchematic of spatiotemporal AKT activity mapping in several organ systems in vivo.Optical window–mediated intravital assessment of metabolic and malignancy-
Oncology February 18,2024
Certain cancers will likely rise exponentially due to COVID-19 screening delays

Certain cancers will likely rise exponentially due to COVID-19 screening delays

byAmerican College of SurgeonsCredit: Unsplash/CC0 Public DomainDelays in cancer screening during the COVID-19 pandemic will likely cause a significant increase in cancer cases that could have b
Oncology February 18,2024
Certain cancers will likely rise exponentially due to COVID-19 screening delays

Certain cancers will likely rise exponentially due to COVID-19 screening delays

byAmerican College of SurgeonsCredit: Unsplash/CC0 Public DomainDelays in cancer screening during the COVID-19 pandemic will likely cause a significant increase in cancer cases that could have b
Oncology February 18,2024
Research suggests a new approach for treatment-resistant breast cancers

Research suggests a new approach for treatment-resistant breast cancers

by Louisiana State UniversityCB-103 shows synergy with paclitaxel and fulvestrant in breast cancer cell lines. TNBC (HCC1187) and ER+ BC (MCF-7) cells were treated with combinations of CB-103 (15
Oncology February 18,2024
Research suggests a new approach for treatment-resistant breast cancers

Research suggests a new approach for treatment-resistant breast cancers

by Louisiana State UniversityCB-103 shows synergy with paclitaxel and fulvestrant in breast cancer cell lines. TNBC (HCC1187) and ER+ BC (MCF-7) cells were treated with combinations of CB-103 (15
Oncology February 18,2024
Researchers find an epigenetic key that unlocks common deadly cancers

Researchers find an epigenetic key that unlocks common deadly cancers

by Katherine Fenz,Rockefeller UniversityLesions (in green) akin to basal cell carcinoma that were induced by SOX9 in the epidermis. Abnormal differentiation is shown in red, and blue marks cell
Oncology February 18,2024
Researchers find an epigenetic key that unlocks common deadly cancers

Researchers find an epigenetic key that unlocks common deadly cancers

by Katherine Fenz,Rockefeller UniversityLesions (in green) akin to basal cell carcinoma that were induced by SOX9 in the epidermis. Abnormal differentiation is shown in red, and blue marks cell
Oncology February 18,2024
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com